COMUNICADO: INVEGA(R) recibe la aprobación en la UE como primer y único tratamiento antisicótico (y 2)

4. Canuso C et al. Paliperidone Extended-Release in Schizoaffective Disorder: A Randomized, Controlled Study Comparing a Flexible Dose With Placebo in Patients Treated With and Without Antidepressants and/or Mood Stabilizers. J Clin Psychopharmacology. 2010;30, 5, 487 - 495.

5. Cheniaux E, Landeira-Fernandez J, Lessa Telles L, et al. Does schizoaffective disorder really exist? A systematic review of the studies that compared schizoaffective disorder with schizophrenia or mood disorders. J Affect Disord. 2008;106, 3, 209-217.

6. Potkin SG, Alphs L, Hsu C, et al. InterSePT Study Group. Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial. Biol Psychiatry. 2003;54, 4, 444-452.

* El doctor Christophe Tessier es un empleado a tiempo completo de Janssen, EMEA

** La doctora Carla M. Canuso es una empleada a tiempo completo de Johnson & Johnson Pharmaceutical Research and Development, LLC, Titusville, NJ

CONTACTO: Para más información contacte con: Sue Silk, Janssen, Tel:+44(0)1494-553955, Email: ssilk@its.jnj.com; Joanna Smith, ResoluteCommunications, Tel: +44(0)207-357-8187, Email:joanna.smith@resolutecommunications.com; contactos con los inversores:LouiseMehrotra +1-732-524-6491; Stan Panasewicz, +1-732-524-2524